Global Short Bowel Syndrome (SBS) Market 2017-2021

  • ID: 4298739
  • Report
  • Region: Global
  • 70 pages
  • TechNavio
OFF
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 5

FEATURED COMPANIES

  • Ardelyx
  • Emmaus Medical
  • Merck
  • Naia Pharmaceuticals
  • Nutrinia
  • OxThera
  • MORE
About Short Bowel Syndrome (SBS)

Short bowel syndrome (SBS) is a metabolic disorder occurs when the portion of the small intestine is not functioning or removed through surgery due to digestive illness. SBS is caused by lack of function of the small intestine. This results in malabsorption, diarrhea, steatorrhea, fluid and electrolyte disturbances, and malnutrition. Based on drug class, the market is segmented into GLP-2, growth hormone, glutamine, and others.

The analysts forecast the global short bowel syndrome (SBS) market to grow at a CAGR of 25.53% during the period 2017-2021.

Covered in this report

The report covers the present scenario and the growth prospects of the global short bowel syndrome (SBS) market for 2017-2021. To calculate the market size, the report considers the sales of the drugs and related nutraceutical products.

The market is divided into the following segments based on geography:
- Americas
- APAC
- EMEA

The report, Global Short Bowel Syndrome (SBS) Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
- Emmaus Medical
- Merck
- Shire

Other prominent vendors
- Ardelyx
- Naia Pharmaceuticals
- Nutrinia
- OxThera
- Sancilio Pharmaceuticals
- Zealand Pharma

Market drivers
- Special drug designations
- For a full, detailed list, view the full report

Market challenges
- Severe side effects of the drugs
- For a full, detailed list, view the full report

Market trends
- Increased awareness of GI disorders
- For a full, detailed list, view the full report

Key questions answered in this report
- What will the market size be in 2021 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

You can request one free hour of the analyst’s time when you purchase this market report. Details are provided within the report.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Ardelyx
  • Emmaus Medical
  • Merck
  • Naia Pharmaceuticals
  • Nutrinia
  • OxThera
  • MORE
PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction
  • Market outline
  • Diagnosis and testing
PART 05: Orphan drug designation

PART 06: Pipeline landscape

PART 07: Market landscape
  • Market overview
  • Five forces analysis
PART 08: Market segmentation by route of administration (ROA)
  • Oral
  • Parenteral
PART 09: Market segmentation by drug class
  • GLP-2
  • Growth hormone
  • Glutamine
  • Others
PART 10: Geographical segmentation
  • SBS market in Americas
  • SBS in EMEA
  • SBS market in APAC
PART 11: Decision framework

PART 12: Drivers and challenges
  • Market drivers
  • Market challenges
PART 13: Market trends
  • Increased awareness of GI disorders
  • Emerging markets
  • Focus on gene therapy
PART 14: Vendor landscape
  • Competitive scenario
PART 15: Key vendor analysis
  • Emmaus Medical
  • Merck
  • Shire
  • Other prominent vendors
PART 16: Appendix
  • List of abbreviations
List of Exhibits
Exhibit 01: Parts of small intestine
Exhibit 02: Causes of SBS
Exhibit 03: Key SBS drugs
Exhibit 04: Diagnostic test for SBS
Exhibit 05: Incentives of orphan drug designation
Exhibit 06: Orphan drugs approved for SBS
Exhibit 07: Overview of case study I
Exhibit 08: Overview of case study II
Exhibit 09: Overview of case study III
Exhibit 10: Global SBS market: Pipeline landscape
Exhibit 11: Global SBS market overview
Exhibit 12: Global SBS market 2016-2021 ($ millions)
Exhibit 13: Opportunity analysis in global SBS market
Exhibit 14: Five forces analysis
Exhibit 15: Segmentation of global SBS market by ROA 2016
Exhibit 16: Market share of global SBS market by ROA 2016 (%)
Exhibit 17: Segmentation of global SBS market by drug class 2016
Exhibit 18: Market share of global SBS market by drug class 2016 (%)
Exhibit 19: Global GLP-2 drugs market 2016-2021 ($ millions)
Exhibit 20: Global SBS human growth hormone market 2016-2021 ($ millions)
Exhibit 21: Global SBS glutamine market 2016-2021 ($ millions)
Exhibit 22: Segmentation of SBS market based on geography 2016 and 2021
Exhibit 23: Global SBS market revenue by geography 2016-2021 ($ millions)
Exhibit 24: Market scenario in Americas
Exhibit 25: SBS market in Americas 2016-2021 ($ millions)
Exhibit 26: Market scenario of EMEA
Exhibit 27: SBS market in EMEA 2016-2021 ($ millions)
Exhibit 28: Market scenario of APAC
Exhibit 29: SBS market in APAC 2016-2021 ($ millions)
Exhibit 30: Key approvals for different regions
Exhibit 31: Competitive structure analysis of global SBS market 2016
Exhibit 32: Strategic success factors of companies in global SBS market
Exhibit 33: Emmaus Medical: Strength assessment
Exhibit 34: Emmaus Medical: Strategy assessment
Exhibit 35: Emmaus Medical: Opportunity assessment
Exhibit 36: Merck: Strength assessment
Exhibit 37: Merck: Strategy assessment
Exhibit 38: Merck: Opportunity assessment
Exhibit 39: Shire: Key highlights
Exhibit 40: Shire: Strength assessment
Exhibit 41: Shire: Strategy assessment
Exhibit 42: Shire: Opportunity assessment
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • Ardelyx
  • Emmaus Medical
  • Merck
  • Naia Pharmaceuticals
  • Nutrinia
  • OxThera
  • MORE
New Report Released: - Global Short Bowel Syndrome (SBS) Market 2017-2021

The author of the report recognizes the following companies as the key players in the global short bowel syndrome (SBS) market: Emmaus Medical, Merck, and Shire.

Other Prominent Vendors in the market are: Ardelyx, Naia Pharmaceuticals, Nutrinia, OxThera, Sancilio Pharmaceuticals, and Zealand Pharma.

Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is increased awareness of GI disorders. Pharmaceutical companies and national and local government bodies such as the health ministry and municipalities are conducting programs to spread awareness of GI disorders. Many NGOs also conduct camps to educate people and raise the awareness level. Drug manufacturers supply visual aids or free samples to physicians and sometimes to individuals to spread awareness of the disorders and promote their drugs. This is done to increase the knowledge of the individuals about a particular GI disorder.”

According to the report, one of the major drivers for this market is special drug designations. As the market is dominated by a few drugs and the pipeline also demonstrates the same, the special designation will provide more opportunity for revenue generation and to expand geographically. These designations carry benefits such as an extension of patent exclusivity period to address the need for an orphan drug, tax credits of up to 50% of R&D costs, and orphan drug’s sponsors are exempted from paying the US FDA application fees. These benefits will reduce the burden from vendors to develop a product for a rare disease.

Further, the report states that one of the major factors hindering the growth of this market is severe side effects of the drugs. The side effects involved in the use of GATTEX may hinder the adoption rates. GATTEX is a GLP-2 analog used for the treatment of adult patients with SBS who are dependent on parenteral support. There is an increased risk that abnormal cells could become cancer. The few other side effects associated with GATTEX is swelling (inflammation) or blockage in gallbladder or pancreas or fluid overload. These side effects could lead to trouble in having a bowel movement or passing gas, stomach area (abdomen) pain or swelling, nausea, vomiting, swelling, and blockage in stoma opening.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 5
  • Emmaus Medical
  • Merck
  • Shire
  • Ardelyx
  • Naia Pharmaceuticals
  • Nutrinia
  • OxThera
  • Sancilio Pharmaceuticals
  • Zealand Pharma
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll